Search

Displaying results 4441 - 4450 of 10000 in total
  1. Drug

    LM-609

    go.drugbank.com/drugs/DB05787
    Experimental

    In addition to cancer, the protein has been implicated in bone destruction in rheumatoid arthritis and the inflammatory process in psoriasis. … LM-609 (Vitaxin) is an artificial antibody that targets a protein on the surface of newly forming blood vessels, as well as on certain tumors.

  2. Drug

    EVT 302

    go.drugbank.com/drugs/DB06057
    Investigational

    EVT 302 is an orally active, potent, highly selective and reversible inhibitor of MAO-B. It is in the development for smoking cessation, and potential for disease modification in Alzheimer's disease.

  3. Drug

    Endostatin

    go.drugbank.com/drugs/DB06423
    Investigational

    Categories: Compounds used in a research, industrial, or household setting, Non-Fibrillar Collagens
  4. Drug

    Nandrolone phenpropionate

    go.drugbank.com/drugs/DB00984
    ApprovedIllicit

    It is generally prepared from alkyl ethers of estradiol to resemble testosterone but less one carbon at the 19 position. It is a schedule III drug in the U.S.

  5. Drug

    NP2

    go.drugbank.com/drugs/DB06308
    Investigational

    It was under investigation in clinical trial NCT01291901 (NP2 Enkephalin For Treatment of Intractable Cancer Pain). … NP2 is a replication defective HSV-1 based gene transfer vector engineered to express human preproenkephalin.

  6. Drug

    Zunsemetinib

    go.drugbank.com/drugs/DB16502
    Investigational

    Zunsemetinib is being investigated in a new clinical trial (NCT06374459) for the treatment of hormone receptor-positive and HER2-negative metastatic breast cancer with bone metastasis. … ATI-450 was under investigation in clinical trials (NCT05279417 and NCT05216224) for treating patients with rheumatoid arthritis and hidradenitis suppurativa, respectively.

    Categories: Experimental Unapproved Treatments for COVID-19
  7. Drug

    Olmutinib

    go.drugbank.com/drugs/DB13164
    Investigational

    Olmutinib recieved breakthrough therapy designation in the United States in December 2015 and was approved for use in Korea in May 2016. … Olmutinib is an orally active epidermal growth factor receptor inhibitor used in the treatment of T790M mutation positive non-small cell lung cancer.

  8. Drug

    NUC B1000

    go.drugbank.com/drugs/DB05242
    Experimental

    [F3910] eiRNA is an approach to RNAi therapeutics, whereby a plasmid DNA coding for desired dsRNA is delivered to diseased cells enabling the cells to carry out dsRNA production internally thereby invoking … On January 11, 2008, it was announced that NUC B1000 was entering a phase 1 human safety study of its experimental treatment for chronic Hepatitis B virus (HBV) infection.

  9. Drug

    Arbaclofen Placarbil

    go.drugbank.com/drugs/DB08892
    Investigational

    by XenoPort in 2011 for the treatment of GERD. … On May 20th, 2013, XenoPort announced plans to terminate the development of Arbaclofen Placerbil for the treatment of multiple sclerosis.

  10. Drug

    Didesmethylrocaglamide

    go.drugbank.com/drugs/DB15496
    Experimental

    [A186760] While traditionally used for their insecticidal benefits,[A186796] this class of compounds is now being studied for use as chemotherapeutic agents in the treatment of various leukemias, lymphomas … Didesmethylrocaglamide is a naturally-occurring derivative of [rocaglamide] and belongs to a class of anti-cancer phytochemicals referred to as "rocaglamides" derived from plants of the genus _Aglaia_.